allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center - LARVOL DELTA

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - P2 | N=24 | Terminated | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=54 ➔ 24 | Trial completion date: Dec 2024 ➔ May 2025 | Active, not recruiting ➔ Terminated; loss of funding

Enrollment change • Trial completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 ➔ Dec 2024

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Jan 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology